Go to content
Attention:

Lukt het niet om in te loggen op het AFM Portaal?

Het kan helpen om uw browsergeschiedenis/cookies te verwijderen

Galapagos NV

Galapagos NV

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 29 jan 2014 - 16:30
Statutaire naam Galapagos NV
Titel First clinical centers opened for Phase 2 Crohn's study with GLPG0634
Bericht First selective JAK1 inhibitor to enter Phase 2 in Crohn's disease 180 patients to be enrolled for 20 weeks of treatment Topline data expected in Q2 2015 Galapagos eligible for $50 M success fee from AbbVie upon study completion Mechelen, Belgium; 29 January 2014 - Galapagos NV (Euronext: GLPG) announced today that the first clinical centers have been opened for enrolment in the Phase 2 clinical study in Crohn's disease with GLPG0634, a selective JAK1 inhibitor. The Phase 2 study will evaluate the efficacy and safety of GLPG0634 during 20 weeks of treatment in 180 patients with active Crohn's disease.